旅行负担对I期和II期乳腺癌治疗的影响:一项美国国家癌症数据库分析
该研究基于美国国家癌症数据库(2018-2020年)293318例激素受体阳性、人表皮生长因子受体2阴性I-II期乳腺癌女性患者,按距治疗机构距离≤20英里或>20英里分组。距离>20英里者接受乳房切除术的几率更高(OR 1.14),接受放疗的几率更低(OR 0.81),倾向性评分匹配后结果一致。
要点
- 距离>20英里的I-II期乳腺癌患者更可能接受乳房切除术(OR 1.14)。
- 距离>20英里的患者接受放疗的可能性更低(OR 0.81)。
- 倾向性评分匹配后上述关联仍然存在。
核心结论
- 激素受体阳性I-II期乳腺癌患者中,旅行负担较大者更可能接受乳房切除术,而接受放疗的可能性更低。
研究设计与样本
- 基于美国国家癌症数据库(2018-2020年)的回顾性队列分析,纳入293318例雌激素受体/孕激素受体阳性且人表皮生长因子受体2阴性的病理I-II期乳腺癌女性患者。
主要发现
- 距离>20英里组患者接受乳房切除术的比例为34.0%,距离≤20英里组为30.4%(P < .001;比值比1.14,P = .016)。
- 距离>20英里组患者接受放疗的比例为60.1%,距离≤20英里组为63.3%(P < .001;比值比0.81,P < .001)。
- 倾向性评分匹配后(每组33544例),距离>20英里组乳房切除术比例为35.3%,距离≤20英里组为30.3%(P < .001)。
- 倾向性评分匹配后(每组33544例),距离>20英里组放疗比例为58.5%,距离≤20英里组为65.4%(P < .001)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Although historic studies of state registries have demonstrated decreased radiation therapy use for patients with breast cancer living further away from radiation facilities, the association between travel distance and breast cancer treatment in a modern national cohort remains unknown. METHODS: Female patients with estrogen receptor/progesterone receptor positive and human epidermal growth factor receptor 2 negative pathologic stages I to II breast cancer were identified from the National Cancer Database (2018-2020) and dichotomized by distance ≤20 miles or >20 miles (75th percentile) from the treatment facility. The association between travel distance and type of surgery and treatment administered was analyzed by univariate and multivariate logistic regression and after 1:1 propensity matching. RESULTS: Of the 293,318 patients identified for inclusion, the median age was 63 years, and most patients (n = 190,567, 65%) lived ≤20 miles of the treatment facility. Patients with a travel burden >20 miles were more likely to receive a mastectomy (≤20 miles 30.4% vs >20 miles 34.0%, P < .001; odds ratio 1.14, P = .016), and less likely to receive radiation (≤20 miles 63.3% vs >20% miles 60.1%, P < .001; odds ratio 0.81, P < .001). These findings persisted after propensity score matching (n = 33,544 per cohort), with patients living further being more likely to undergo a mastectomy (≤20 miles 30.3% vs >20 miles 35.3%, P < .001) and less likely to receive radiation (≤ 20 miles 65.4% vs. >20 miles 58.5%, P < .001). CONCLUSION: Patients with hormone receptor-positive stage I to II breast cancer with a larger travel burden are more likely to receive a mastectomy and less likely to undergo radiation therapy to treat their disease.
引用
- Perry NJ, Sharon CE, Tortorello GN, et al. Impact of travel burden on the treatment of stage I and II breast cancer: A National Cancer Database analysis. Surgery. 2023. PMID: 37562985. doi:10.1016/j.surg.2023.07.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。